The 41st stock acquisition rights will be allocated to EVO FUND by third-party allotment for 200,000 units with an exercise price adjustment clause. The 42nd stock acquisition rights will be allocated to Mr. Ryo Kubota by third-party allotment for 200,000 units with a fixed exercise price of 60 yen and a full ratchet clause. Funds are intended to secure research and development, commercialization expenses and working capital, with a total of approx. 2,380 million yen and detailed disclosure of fund use. Reasonableness of issuance terms, dilution explanations, and the Audit and Supervisory Committee’s opinion are also provided.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4596","jir_company_name":"Kubota Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4596-20261023-01.pdf","jir_short_summary":"The 41st stock acquisition rights will be allocated to EVO FUND by third-party allotment for 200,000 units with an exercise price adjustment clause. The 42nd stock acquisition rights will be allocated to Mr. Ryo Kubota by third-party allotment for 200,000 units with a fixed exercise price of 60 yen and a full ratchet clause. Funds are intended to secure research and development, commercialization expenses and working capital, with a total of approx. 2,380 million yen and detailed disclosure of fund use. Reasonableness of issuance terms, dilution explanations, and the Audit and Supervisory Committee's opinion are also provided.","jir_summary":"### Summary of Capital Policy and Fundraising\nKubota Pharmaceutical Holdings Co., Ltd. announced a third-party allotment of 200,000 units of the 41st stock acquisition rights to EVO FUND and a third-party allotment of 200,000 units of the 42nd stock acquisition rights to Mr. Ryo Kubota. The 41st rights include an exercise price adjustment clause, partial exercise commitment conditions and exercise suspension provisions, and the funds raised will be allocated to R&D expenses and working capital. The 42nd rights have a fixed exercise price of 60 yen with a full ratchet clause and a long exercise period. The total is estimated at approximately 2,380 million yen. The notice also describes obtaining the Audit and Supervisory Committee's opinion and conditions for amending issuance terms, and explains that dilution of existing shareholders will occur.\n\n### Outlook and Risks\nFunds are planned to be applied to R&D, commercialization expenses and working capital from 2027 onward. Development of emixstat hydrochloride will continue, and domestic and international partnerships will be pursued, including utilization of a Compassionate Use Program in France and regulatory responses. However, risks include dilution of shares and variability of funds raised depending on the exercise status of the 41st and 42nd rights, which could also affect the share price.","jir_financial_highlights":"Amount of funds to be raised: 2,380 million yen (Estimate based on the total subscription payments and total assets contributed under the stock acquisition rights)\nTotal number of stock acquisition rights to be issued: 41st: 200,000 units, 42nd: 200,000 units (By allottee)\nNumber of potential shares: 41st: 20,000,000 shares, 42nd: 20,000,000 shares (Potential shares after issuance)","jir_category":"","jir_hashtags":"#KubotaPharmaceuticalHoldings, #CapitalPolicy, #StockAcquisitionRights, #ThirdPartyAllotment","jir_key_figures":"41st stock acquisition rights: 200,000 units\n42nd stock acquisition rights: 200,000 units\nAmount of funds to be raised: 2,380 million yen","jir_meta_title":"Kubota Pharmaceutical Holdings Co., Ltd. Announces Issuance and Purchase Agreement of Stock Acquisition Rights\uff5cNovember 9, 2026","jir_meta_description":"Kubota Pharmaceutical Holdings Co., Ltd. announced allocation of the 41st stock acquisition rights to EVO FUND and the 42nd stock acquisition rights to Mr. Ryo Kubota. Funds will be used for R&D and working capital; issuance terms combine an adjustment clause and a fixed exercise price. Details on dilution and future fundraising strategy are provided.","jir_og_title":"Kubota Pharmaceutical Holdings Co., Ltd. Announces Issuance of Stock Acquisition Rights\uff5cNovember 9, 2026","jir_og_description":"Kubota Pharmaceutical allocates the 41st stock acquisition rights to EVO FUND and the 42nd to Mr. Ryo Kubota. Funds will be applied to R&D and working capital. Disclosure includes dilution risk and the Audit and Supervisory Committee's opinion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59981,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-133958","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n